Month: September 2026

GLYFADA, Greece, Sept. 14, 2026 (GLOBE NEWSWIRE) — Globus Maritime Limited (the “Company” or “Globus”) (NASDAQ: GLBS), a dry bulk shipping company, announced today that it has taken delivery of the M/V “Glbs Olympia,” a 2026 new built Ultramax dry bulk carrier it acquired and which the Company had previously announced on August 23, 2023.

The M/V “Glbs Olympia” was built at the Nihon Shipyard Co in Japan and has a carrying capacity of approximately 64,000 DWT.

Athanasios Feidakis President and CEO of Globus commented:

“We are pleased to announce the delivery of our fourth Ultramax newbuilding from a reputable shipbuilder, marking another important milestone in the ongoing renewal and modernization of our fleet. The addition of this modern, fuel-efficient vessel further strengthens our operational capabilities and efficiency. Our fleet renewal strategy remains focused on investing in high-quality, commercially competitive tonnage that is well positioned to meet the evolving requirements of the global shipping industry.

“We remain committed to disciplined growth and the selective expansion of our fleet, while maintaining a prudent approach to capital allocation. By strengthening our competitive position and enhancing the quality and efficiency of our fleet, we aim to deliver sustainable, long-term value to our shareholders.”

Following this acquisition, the fleet of Globus comprises of ten dry bulk carriers with a total carrying capacity of approximately 744,622 DWT.

About Globus Maritime Limited

Globus is an integrated dry bulk shipping company that provides marine transportation services worldwide and presently owns, operates and manages a fleet of ten dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina and other dry bulk cargoes internationally. Globus’ subsidiaries own and operate ten vessels with a total carrying capacity of approximately 744,622DWT and a weighted average age of about 8 years as of September 14, 2026.

Safe Harbor Statement

This communication contains “forward-looking statements” as defined under U.S. federal securities laws. Forward-looking statements provide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts or that are not present facts or conditions. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The Company’s actual results could differ materially from those anticipated in forward-looking statements for many reasons specifically as described in the Company’s filings with the Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this communication. Globus undertakes no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this communication or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks Globus describes in the reports it files from time to time with the Securities and Exchange Commission.

For further information please contact:

Globus Maritime Limited	+30 210 960 8300
Athanasios Feidakis	a.g.feidakis@globusmaritime.gr
Capital Link – New York	+1 212 661 7566
Nicolas Bornozis	globus@capitallink.com

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfolio. To date, UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance.

In the U.S., there are approximately 85,000 patients diagnosed with bladder cancer annually, including about 65,000 with NMIBC. Of the 750,000 patients living with bladder cancer, approximately 600,000 are living with NMIBC.

NMIBC is generally confined to the bladder and may shed only limited tumor DNA into the bloodstream, which can make blood-based detection challenging. Urine, by contrast, comes into direct contact and can provide a highly relevant source of tumor-derived genomic information. UroAmp analyzes this information, creating the potential to help inform treatment decisions and monitor patients throughout their care.

“Bladder cancer care is advancing quickly, yet clinicians and patients still face significant uncertainty at critical decision points,” said Marc Stapley, Veracyte’s chief executive officer. “UroAmp brings a differentiated urine-based platform that is especially well suited to non-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD tests, this acquisition strengthens Veracyte’s ability to deliver complementary insights from urine, tissue, and blood to help guide care across the bladder cancer continuum.”

UroAmp is supported by a robust and growing body of evidence, including nine peer-reviewed publications and more than 40 posters and abstracts. Veracyte’s initial test will be intended to help determine whether patients who have completed Bacillus Calmette-Guerin (BCG) induction therapy are likely to benefit from maintenance treatment. The company expects to commercialize this test in late 2028, subject to reimbursement timelines. Veracyte also plans to expand its use of the UroAmp platform to additional indications, including intravesical maintenance therapy monitoring and surveillance following treatment with curative intent.

In the RUMBLE study published in The Journal of Urology, a multicenter prospective clinical validation study, patients who were clinically negative following induction BCG treatment but tested positive for utDNA had a 12-month recurrence-free survival rate of 25%, compared with 91% among utDNA-negative patients.¹

“This acquisition brings together UroAmp’s differentiated platform and scientific expertise with Veracyte’s evidence-generation capabilities, commercial infrastructure, and established relationships,” said Brian Slingerland, chief executive officer, Convergent Genomics. “We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer.”

The acquisition includes $150 million in upfront cash consideration and up to $30 million in additional cash consideration tied to key milestones related to UroAmp reimbursement efforts. Veracyte contemplated the ongoing operating expenses of Convergent in its previously provided 2026 adjusted EBITDA guidance and is not updating such guidance at this time.

About Convergent Genomics

Convergent Genomics was founded in 2015 by Trevor Levin, PhD, chief scientific officer, and a team of cancer biologists, urologic oncologists, and data scientists, in partnership with Oregon Health & Science University (OHSU) and Illumina Accelerator. The company has received multiple peer-review grants from the National Cancer Institute and is engaged in research with over 30 sites worldwide, including leading academic centers. Convergent Genomics operates its clinical laboratory in South San Francisco that is certified by the California Department of Public Health and nationally by CLIA-CMS. For more information visit www.convergentgenomics.com.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the anticipated short and long term strategic, clinical, commercial and financial benefits of the acquisition; the expected impact of the acquisition on Veracyte’s near-term financial outlook; development, launch, commercialization, reimbursement and timing of tests based on the acquired technology, including UroAmp; the anticipated timing of launch of the first product; estimated market opportunities; potential commercial synergies; potential applications of UroAmp in other urological diseases; and ability to achieve anticipated milestones.

Forward-looking statements can be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” “could” and similar expressions. Actual results may differ materially due to risks and uncertainties, including Veracyte’s ability to integrate Convergent, retain key employees, achieve anticipated benefits of the acquisition, meet development timelines, demonstrate clinical validity and utility of acquired products, obtain reimbursement for acquired products and commercialize new tests, including UroAmp.

Additional factors are described under “Risk Factors” in Veracyte’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release, and Veracyte disclaims any obligation to update them except as required by law.

Investors:
Kelly Gura
investors@veracyte.com

Media:
Molly Cornbleet
media@veracyte.com
+1 650-351-8780

¹ Bahlburg H, Maas M, Contreras-Sanz A, et al. Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin. J Urol. 2026;216(3):388-399. doi:10.1097/JU.0000000000005130.

DELRAY BEACH, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) — PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately. Parry will lead the Company’s technology strategy, platform architecture and engineering execution across its e-commerce, pharmacy and enterprise systems.  

Parry brings more than three decades of technology leadership experience and joins PetMeds from The ODP Corporation, where he most recently served as Senior Vice President and Chief Information Officer, leading technology for the retail, business solutions and supply-chain units. In that role, he executed a multi-year initiative to embed generative AI and workflow automation across the business and led platform-modernization efforts including e-commerce and order-management. Prior to his appointment as Chief Information Officer in 2023, Parry spent nearly two decades at Office Depot in technology leadership roles of progressive responsibility across application development, customer-facing systems, and enterprise architecture and business intelligence.

“Andrew’s track record modernizing complex, customer-facing platforms while driving real cost efficiency makes him the right leader to continue strengthening our technology foundation,” said Leslie C.G. Campbell, Interim Chief Executive Officer and President of PetMeds. “His experience leading large-scale transformations in high-volume environments will be critical in driving execution discipline, delivery excellence and operational rigor.”  

“PetMeds has a 30-year legacy of making pet healthcare more accessible, and its pharmacy infrastructure and loyal customer base give it a strong foundation to build on,” said Andrew Parry, Chief Technology Officer of PetMeds. “I look forward to working with the team to continue modernizing our platforms, leveraging technology to drive scale, optimize performance and enhance the customer experience.”

About PetMeds

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions — including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.

Forward-Looking Statements

This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

Investor Contact
ICR, LLC
Reed Anderson
investor@petmeds.com

– Acquired Significantly Below Replacement Cost –
– Property Provides Long-Term Repositioning Opportunity –
– 2026 Year-to-Date Investments Total $334 Million –

WINTER PARK, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced the acquisition of Zona Rosa, a 768,000 square foot mixed-use center located in Kansas City, Missouri, for $63.3 million, or $82 per square foot. The Company believes the combination of strong market demographics combined with its proven expertise to extract meaningful value from prior repositioning executions will provide the opportunity to produce a compelling initial yield and long-term return.

“With the addition of this new property, our year-to-date property acquisition volume now exceeds $200 million at a blended entry cash cap rate of 8.2%, and, with structured investments, activity totals $334 million at a blended initial cash yield of 9.5%,” said John P. Albright, President and Chief Executive Officer of CTO Realty Growth, Inc. “Zona Rosa is a leading mixed-use center located in one of Kansas City’s fastest-growing neighborhoods, ringed by average household income levels of $124,000 within 5 miles.”

Zona Rosa will be a long-term, multi-phase revitalization opportunity with substantial embedded upside via leasing and repositioning opportunities. The property is currently 67% leased, anchored by Dick’s Sporting Goods, Barnes & Noble, Old Navy, Burlington, and DSW. The 768,000-square foot, 64-acre center includes 10 acres of entitled development land and approximately 100,000 square feet of underutilized space for future value-add repositioning.

Zona Rosa is a leading retail, dining, and entertainment destination serving Kansas City’s Northland, with no comparable center within a 20-minute drive, attracting approximately 5.5 million visits annually. The property is located six miles from Kansas City International Airport, which recently completed a $1.5 billion new terminal, and its five-mile trade area has a population of approximately 100,000.

About CTO Realty Growth, Inc.

CTO Realty Growth, Inc. owns and operates high-quality, open-air shopping centers located primarily in the higher growth Southeast and Southwest markets of the United States. CTO also externally manages and owns a meaningful interest in Alpine Income Property Trust, Inc. (NYSE: PINE), a publicly traded net lease REIT.

We encourage you to review our most recent investor presentation and supplemental financial information, which is available on our website at www.ctoreit.com.

Safe Harbor

Certain statements contained in this press release (other than statements of historical fact) are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can typically be identified by words such as “opportunity,” “upside,” “outlook,” “believe,” “estimate,” “expect,” “intend,” “anticipate,” “will,” “could,” “may,” “should,” “plan,” “potential,” “predict,” “forecast,” “project,” and similar expressions, as well as variations or negatives of these words. Statements, among others, relating to the opportunity for a compelling initial return and substantial embedded upside for Zona Rosa and potential earnings growth through lease-up, long-term redevelopment opportunities are forward-looking statements.

Although forward-looking statements are made based upon management’s present expectations and beliefs concerning future developments and their potential effect upon the Company, a number of factors could cause the Company’s actual results to differ materially from those set forth in the forward-looking statements. Such factors may include, but are not limited to: the Company’s ability to remain qualified as a REIT; the Company’s exposure to U.S. federal and state income tax law changes, including changes to the REIT requirements; general adverse economic and real estate conditions; macroeconomic and geopolitical factors, including but not limited to inflationary pressures, interest rate volatility, ongoing geopolitical war, distress in the banking sector, and global supply chain disruptions, and ongoing geopolitical war; credit risk associated with the Company investing in commercial loans, preferred equity, and similarly structured investments; the ultimate geographic spread, severity and duration of pandemics such as the COVID-19 Pandemic and its variants, actions that may be taken by governmental authorities to contain or address the impact of such pandemics, and the potential negative impacts of such pandemics on the global economy and the Company’s financial condition and results of operations; the inability of major tenants or borrowers to continue paying their rent or obligations due to bankruptcy, insolvency or a general downturn in their business; the loss or failure, or decline in the business or assets of PINE; the completion of 1031 exchange transactions; the availability of investment properties that meet the Company’s investment goals and criteria; the uncertainties associated with obtaining required governmental permits and satisfying other closing conditions for planned acquisitions and sales; and the uncertainties and risk factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other risks and uncertainties discussed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission.

There can be no assurance that future developments will be in accordance with management’s expectations or that the effect of future developments on the Company will be those anticipated by management. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

CONTACT: Contact:
Investor Relations
ir@ctoreit.com

TAIPEI, Taiwan, Sept. 14, 2026 (GLOBE NEWSWIRE) — Asia Pacific Wire & Cable Corporation Limited (NASDAQ: APWC) (“APWC” or the “Company”) today announced shareholder approval of all resolutions proposed at the 2026 Annual General Meeting of Shareholders (“AGM”) held on September 11, 2026.

“We would like to thank our shareholders for their participation in this year’s Annual General Meeting in person or via telephone conference and for their continued support of the Company,” said Mr. Yuan, APWC’s Chief Executive Officer (“CEO”).

Key Takeaways from the 2026 AGM: APWC’s management reviewed the 2026 Investor Presentation, providing an operational and financial update, highlighting the Company’s first-half 2026 performance, Asia-Pacific investment plans, structural optimization initiatives, and corporate strategies. 

1. First Half 2026 Financial Performance

• Revenue Growth: H1 2026 revenue increased 17.6% year-over-year to US$267.5 million.
• Margin Expansion: EBITDA margin improved to 4.56% from 1.66% in the prior-year period.
• Strong Liquidity: Cash balances increased to US$64.6 million following the successful rights offering completed in Q1 2026.

2. Power Infrastructure Opportunity

• APWC highlighted its expanding role in regional power and energy infrastructure solutions.
• Approximately SGD 1 billion in power infrastructure projects in Singapore, expected to be executed over the next four years.
• Developing the Singapore platform into a regional hub capable of supporting energy storage, AI data center and infrastructure solutions, as well as supply chain management center.

3. Growth Beyond Traditional Wire & Cable

APWC continues to expand downstream into higher value-added business segments, aimed to enhance long-term margin profits and diversify revenue streams. Key growth areas include:

• Energy storage and power infrastructure solutions.
• Engineering, Procurement, and Construction (EPC) and Operation & Maintenance (O&M) services.
• On-train communication systems.
• Public transportation infrastructure projects.

4. North America Expansion

• APWC is actively evaluating investment opportunities in and around the State of Texas.
• Opportunities being explored include association with the TEEMA Industry Park and Taiwan Tower initiatives as potential market-entry platforms.
• Discussions with partners and customers regarding North American market expansion are in progress.

5. Management Commentary

“We believe APWC is entering a new phase of development, building upon our established wire and cable business while expanding into energy infrastructure, communication systems, and international growth opportunities. Our investment strategy remains focused on long-term value creation.“ commented APWC’s CEO.

Available for review on the Company’s website are the H1 2026 financial results and 2026 Investor Presentation. APWC reminds shareholders and investors that corporate news, initiatives, and financial disclosures are published on its website at APWC Website – Investor Relations.

• H1 Financial Results: 2026 H1 Income Statement
• 026 Investor Presentation: Investor Relations / Investor Presentation.

About Asia Pacific Wire & Cable Corporation Limited

Asia Pacific Wire & Cable Corporation Limited is a holding company incorporated in Bermuda with principal executive offices in Taiwan that conducts its business through operating subsidiaries. Through these subsidiaries, the Company is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, the People’s Republic of China, Hong Kong and certain other markets in the Asia Pacific region. The Company also engages in the distribution of various wire and cable products manufactured by its controlling shareholder, Pacific Electric Wire & Cable Co., Ltd., and certain third parties. The Company also provides project engineering services in the supply, delivery and installation of power cable. The Company’s major customers include appliance component manufacturers, electrical contracting firms, state owned entities, and wire and cable dealers and factories.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the Company, its business, and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes”, “anticipates”, “expects”, “estimates”, “intends”, “plans” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as believed, anticipated, expected, estimated, intended or planned. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company, or to persons acting on its behalf, are expressly qualified in their entirety by these factors, other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.

Investor Relations Contact:

Pacific Holdings Group

2901 Dallas Parkway, Suite 360

Plano, TX 75093

Attn: Paul Weber

Phone: (469) 797-7191

Email: pweber@pusa.com

Agreement Removes Fixed Expiration Date and Requires 48 Months’ Advance Notice to Terminate, Providing a Minimum Four-Year Term at All Times

ST. PETERSBURG, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) — American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”), the insurance holding company of American Coastal Insurance Company (“AmCoastal”), announced today that AmCoastal and AmRisc, LLC (“AmRisc”) have restructured their exclusive managing agency agreement, effective July 1, 2026, to remove the agreement’s fixed expiration date. The prior agreement, extended in June 2024, was scheduled to expire on January 1, 2029.

The restructured agreement provides for successive one-year terms that automatically renew, and requires either party to provide 48 months’ advance written notice in order to terminate the agreement for convenience, with the agreement remaining in full force and effect through the notice period. As a result, the agreement has no fixed expiration date and will remain in effect for a minimum of four years from the date any such notice is given.

AmRisc has been AmCoastal’s exclusive distribution and underwriting partner since 2007. AmRisc sources and underwrites the Florida commercial-residential portfolio, and has been profitable in every year since inception. AmRisc is also the Company’s partner in excess and surplus lines. The quota share supporting AmRisc’s nationwide E&S commercial property book added premium to our growing excess and surplus portfolio. Removing the fixed expiration date secures the distribution source behind the Company’s core Florida franchise and the durability of the broader AmRisc relationship.

“AmRisc has been our exclusive distribution and underwriting partner since 2007, and this agreement puts that partnership on a permanent footing,” said Brad Martz, President & CEO. “By removing the fixed expiration date and requiring four years’ notice to terminate, we have given shareholders long-term visibility into the franchise that has produced an underwriting profit every year since inception, and a strong foundation under our most important distribution relationship.”

About American Coastal Insurance Corporation:
American Coastal Insurance Corporation (amcoastal.com) is the holding company of the insurance carrier, American Coastal Insurance Company, which was founded in 2007 for the purpose of insuring Condominium and Homeowner Association properties, Apartments and Assisted Living Facilities in the state of Florida. American Coastal Insurance Company has an exclusive partnership for distribution of Condominium Association properties in the state of Florida with AmRisc Group (amriscgroup.com), one of the largest Managing General Agents in the country specializing in hurricane-exposed properties. American Coastal Insurance Company has earned an “A”, (“Exceptional”) Financial Stability Rating from Demotech and maintains an “A” insurance financial strength rating with a Stable outlook from KBRA. ACIC maintains a “BBB” issuer rating with a Stable outlook from KBRA.

Contact Information:
Alexander Baty
Vice President, Finance & Investor Relations, American Coastal Insurance Corporation
investorrelations@amcoastal.com
(727) 425-8076

Glen Akselrod
President & Founder, Bristol Investor Relations
ga@bristolir.com
(905) 326-1888

• Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for patients with RAS-addicted cancers

REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company’s RAS(ON) multi-selective inhibitor, for treatment-naïve metastatic pancreatic adenocarcinoma (PDAC) in combination with gemcitabine and nab-paclitaxel (GnP), a multiagent chemotherapy regimen widely used in treating patients with PDAC. RASONQUE was recently approved by the U.S. FDA for the treatment of adult patients with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

The Breakthrough Therapy Designation is based on data from patients with treatment-naïve RAS mutant metastatic PDAC who received RASONQUE in combination with GnP in the open-label, multicenter Phase 1/2 RMC-GI-102 trial. In this cohort, RASONQUE in combination with GnP showed encouraging preliminary antitumor activity and a manageable safety profile that was consistent with the known safety profiles previously observed for both RASONQUE and GnP. These data informed the design of RASolute 303, the ongoing global Phase 3 trial evaluating RASONQUE as monotherapy and in combination with GnP versus GnP alone in patients with previously untreated metastatic PDAC, independent of tumor RAS genotype. The use of RASONQUE in combination with chemotherapy for treatment-naïve metastatic PDAC remains investigational with safety and efficacy not yet established.

“This Breakthrough Therapy Designation underscores the significant unmet need among patients with previously untreated metastatic pancreatic adenocarcinoma and recognizes the importance of advancing new treatment options earlier in their treatment journey,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “RASONQUE monotherapy demonstrated compelling clinical benefit in the RASolute 302 trial, leading to FDA approval for patients with previously treated metastatic pancreatic adenocarcinoma or those who are not candidates for multiagent systemic therapy. Data from the RMC-GI-102 study have now shown the therapeutic potential of RASONQUE in combination with GnP, a commonly used multiagent systemic therapy, in treatment-naïve patients. Together with our other ongoing studies, these findings reflect our deep commitment to advancing a broad RAS(ON) approach for patients with some of the most difficult-to-treat cancers.”

Breakthrough Therapy Designation is intended to expedite the development and review of potential new medicines designed to treat serious conditions and address significant unmet medical needs. Pursuant to FDA guidelines, the medicine needs to have shown preliminary clinical evidence that demonstrates substantial improvement on a clinically significant endpoint over available medicines.

About Pancreatic Adenocarcinoma (PDAC)
Pancreatic adenocarcinoma, or PDAC, is the most common form of pancreatic cancer and among the most challenging malignancies. Approximately 55,000 people are diagnosed with PDAC in the U.S. each year, and more than 50,000 die from the disease with current standard of care.^1,2 Because early-stage pancreatic cancer often causes few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread, when treatment options are more limited. For patients with metastatic PDAC, the five-year relative survival rate is approximately 3% in the U.S.^3.4

About RASONQUE^TM (daraxonrasib)
RASONQUE (daraxonrasib) is an oral, RAS(ON) multi-selective, noncovalent, tri-complex inhibitor (TCI), approved by the U.S. FDA for the treatment of adult patients with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.⁵ RASONQUE is being investigated through a global Phase 3 registrational program in patients with PDAC and metastatic RAS mutant non-small cell lung cancer (NSCLC). Outside the U.S., RASONQUE is an investigational agent that has not been approved by any regulatory authority.

U.S. FDA APPROVED INDICATION
RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

IMPORTANT SAFETY INFORMATION FOR U.S. APPROVED INDICATION
RASONQUE is associated with the following Warnings and Precautions: Dermatologic and Soft Tissue Toxicity, Stomatitis and Oral Disorders, Diarrhea, Gastrointestinal Perforation, Interstitial Lung Disease (ILD)/Pneumonitis, and Embryo-Fetal Toxicity.

WARNINGS AND PRECAUTIONS

Dermatologic and Soft Tissue Toxicity
RASONQUE can cause dermatologic toxicity, which may be severe. Clinical manifestations included, but were not limited to, rash, pruritus, paronychia, dry skin, and skin fissures. In clinical trials of patients with pancreatic adenocarcinoma, dermatologic toxicity occurred in 86% of patients treated with RASONQUE, of which 10% were Grade 3.

Monitor patients who develop dermatologic or soft tissue toxicities while receiving RASONQUE. Initiate prophylactic measures (e.g., topical corticosteroids, emollient creams, sunscreen, oral antibiotics) prior to the first dose of RASONQUE to reduce the risk of moderate to severe dermatologic reactions. Advise patients to limit sun exposure while taking RASONQUE. Initiate supportive measures (e.g., oral corticosteroids) as clinically indicated, and consider dermatologic consultation. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Stomatitis and Oral Disorders
RASONQUE can cause stomatitis, including mouth ulcers and oral mucositis. In clinical trials of patients with pancreatic adenocarcinoma, stomatitis occurred in 57% of patients, of which 9% were Grade 3.

Monitor patients for signs and symptoms of stomatitis while receiving RASONQUE. Initiate a steroid-containing mouthwash for treatment of stomatitis and administer other topical treatments (e.g., chlorhexidine mouthwash, 2% lidocaine viscous) as clinically indicated. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Diarrhea
RASONQUE can cause diarrhea. In clinical trials of patients with pancreatic adenocarcinoma, diarrhea occurred in 63% of patients, of which 6% were Grade 3.
If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Gastrointestinal Perforation
RASONQUE can cause gastrointestinal perforation. In clinical trials of patients with pancreatic adenocarcinoma, gastrointestinal perforation occurred in 0.9% of patients treated with RASONQUE, of which 0.5% were Grade 3, one event was Grade 4, and one event was fatal.

Monitor patients for gastrointestinal perforation. Withhold RASONQUE if gastrointestinal perforation is suspected. Reduce the dose or permanently discontinue RASONQUE if no other potential causes of gastrointestinal perforation are identified.

Interstitial Lung Disease (ILD)/Pneumonitis
RASONQUE can cause interstitial lung disease or pneumonitis. In clinical trials of patients with pancreatic adenocarcinoma, ILD/pneumonitis occurred in 2.4% of patients treated with RASONQUE, of which 0.9% were Grade 3, and one event was fatal.

Monitor patients for new or worsening pulmonary symptoms. Withhold RASONQUE if ILD/pneumonitis is suspected. Reduce the dose or permanently discontinue RASONQUE if no other potential causes of ILD/pneumonitis are identified.

Embryo-Fetal Toxicity
Based on findings in animals, RASONQUE can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with RASONQUE and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with RASONQUE and for 1 week after the last dose.

ADVERSE REACTIONS
Serious adverse reactions occurred in 30% of patients treated with RASONQUE. Serious adverse reactions occurring in ≥ 2% of patients treated with RASONQUE were diarrhea (3.7%), pyrexia (3.3%), sepsis (2.9%), fatigue (2.1%), and hemorrhage (2.1%).

Adverse reactions leading to permanent discontinuation of RASONQUE occurred in 2.9% of patients, including two patients who discontinued due to rash (0.8%).

The most common (≥ 20%) adverse reactions in patients treated with RASONQUE were rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

DRUG INTERACTIONS

• Strong CYP3A Inhibitors with P-gp Inhibition: Avoid concomitant use.
• Strong CYP3A Inhibitors without P-gp Inhibition: Reduce RASONQUE dosage.
• Moderate CYP3A Inhibitors with or without P-gp Inhibition: Reduce RASONQUE dosage.
• P-gp Inhibitors: Reduce RASONQUE dosage.
• Cyclosporine A: Avoid concomitant use.
• Strong CYP3A Inducers: Avoid concomitant use. Increase RASONQUE dosage if concomitant use cannot be avoided.
• Moderate CYP3A Inducers: Increase RASONQUE dosage.
• P-gp Substrates: Take at least 4 hours apart from RASONQUE.

PROPHYLACTIC MEASURES
When initiating RASONQUE and throughout treatment, prophylactic and concomitant medications are recommended to reduce the risk of dermatologic reactions:

• administer a topical corticosteroid (applied to the face and chest) and emollient creams;
• advise patients to limit sun exposure and use broad-spectrum sunscreen (SPF 30 or higher); and
• consider prophylactic oral antibiotics (e.g., doxycycline or minocycline).

Please see U.S. Full Prescribing Information for RASONQUE

About Revolution Medicines, Inc.
Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the broad potential of RAS(ON) inhibition; treatment practices; the company’s regulatory interactions and the potential for Breakthrough Therapy Designation to expedite the development and review of new medicines; reactions to RASONQUE; and progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company’s candidates being studied.

Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “potential,” “project,” “up to,” “will” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contacts 

Media
media@revmed.com  

Investors
investors@revmed.com 

References

¹ Oracle CancerMPact Patient Metrics, Stage IV newly incident + recurrent from earlier stages. Accessed July 2026.
² Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820
³ Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. Cell. 2023;186(8):1729-1754. doi:10.1016/j.cell.2023.02.014
⁴ American Cancer Society. Survival Rates for Pancreatic Cancer. Available at: https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html. Accessed September 2026.
⁵ RASONQUE (daraxonrasib) Prescribing Information. Redwood City, CA: Revolution Medicines, Inc.; August 2026.

DALLAS, Sept. 14, 2026 (GLOBE NEWSWIRE) — Dave & Buster’s Entertainment, Inc. (NASDAQ: PLAY) (“Dave & Buster’s” or “the Company”), an owner, operator, and franchisor of entertainment and dining venues, today announced financial results for its second quarter of fiscal 2026 ended August 4, 2026.

Second Quarter 2026 Financial Summary

• Revenue of $544.1 million decreased 2.4% from the second quarter of fiscal 2025.
• Comparable store sales decreased 2.9% compared to the same calendar period in fiscal 2025.
• Net loss totaled $12.5 million, or a $0.36 net loss per diluted share, compared to net income of $11.4 million, or $0.32 net income per diluted share in the second quarter of fiscal 2025. Adjusted net loss¹ totaled $9.5 million, or a $0.27 Adjusted net loss per diluted share, compared to Adjusted net income¹ of $14.2 million, or $0.40 Adjusted net income per diluted share in the second quarter of fiscal 2025.
• Adjusted EBITDA¹ was $98.9 million compared to $129.8 million in the second quarter of fiscal 2025.
• Adjusted free cash flow¹ was positive $19.5 million for the six months ended August 4, 2026 compared to negative $36.5 million through the end of the six months ended August 5, 2025.

Additional Events and Commentary

• The Company opened six new domestic stores in the second quarter.
• The Company expects to complete two additional Dave & Buster’s store remodels during the remainder of fiscal 2026, bringing the total number of remodels completed in fiscal 2026 to eight.
• The Company has six international franchise stores and expects to open at least one additional international franchise store during the remainder of fiscal 2026.

“We are energized by the obvious, actionable, and enormous opportunities ahead for Dave & Buster’s and Main Event,” said Darin Harper, Chief Executive Officer. “Our Back-to-Basics strategy is gaining momentum with enhanced executional urgency. We are experiencing ongoing growth in food and beverage sales as well as in special events sales. The same store sales of our remodels continue to outperform the system. Further, we improved overall same store sales in July, and saw continued improvement in overall same store sales during the third quarter to date. We are laser focused on returning to same-store sales and EBITDA growth, sharpening our margin management with cost saving initiatives, generating significant free cash flow, and delivering meaningful shareholder value. I have tremendous confidence in the direction of our business and am excited about what we will accomplish together as we shape the future of our company.”

______________________
¹ Adjusted EBITDA, Adjusted net income (loss) and Adjusted free cash flow are non-GAAP financial measures. Please see the discussion under Non-GAAP Measures and the reconciliations at the end of this release for additional information concerning these and other non-GAAP financial measures.

Cash Flow and Liquidity

The Company generated $19.5 million in Adjusted free cash flow for the six months ended August 4, 2026, ending the quarter with $492.1 million of available liquidity¹.

Quarterly Report on Form 10-Q Available

The Company’s Quarterly Report on Form 10-Q, which will be available at www.sec.gov and on the Company’s investor relations website, contains a thorough review of its financial results for the second quarter ended August 4, 2026.

Investor Conference Call and Webcast

Management will host a conference call to discuss these results on Monday, September 14, 2026 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time). Both the live and archived webcasts of the conference call will be available at ir.daveandbusters.com. Participants in the U.S. can access the conference call by dialing toll-free (888) 596-4144, and international participants can access by dialing +1 (646) 968-2525. The conference ID is 3278311. A replay will be available after the call beginning at 6:00 p.m. Central Time (7:00 p.m. Eastern Time) and can be accessed by dialing toll-free (800) 770-2030 or by the toll number +1 (609) 800-9909. The replay conference ID is also 3278311.

About Dave & Buster’s Entertainment, Inc.

Founded in 1982 and headquartered in Coppell, Texas, Dave & Buster’s Entertainment, Inc. is the owner and operator of 250 stores in North America that offer premier entertainment and dining experiences to guests through two distinct brands: Dave & Buster’s and Main Event. The Company has 184 Dave & Buster’s branded stores in 43 states, Puerto Rico, and Canada, and offers guests the opportunity to “Eat, Drink, Play, and Watch” all in one location. Each store offers a full menu of entrées and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The Company also operates 66 Main Event branded stores in 24 states across the country, and offers state-of-the-art bowling, laser tag, hundreds of arcade games and virtual reality, making it the perfect place for families to connect and make memories. Internationally, the Company is in early-stage growth as a franchisor of its brands with six Dave & Buster’s franchise stores currently open. For more information about each brand, visit daveandbusters.com and mainevent.com.

Forward-Looking Statements

The Company cautions that this release contains statements that are, or may be deemed to be, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will” or “should” or, in each case, their negative or other variations or comparable terminology. Forward-looking statements are neither historical facts nor assurances of future performance, and are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These forward-looking statements include all matters that are not historical facts, including statements regarding our intentions, beliefs or current expectations concerning, among other things: our results of operations; financial condition; liquidity; prospects; growth; strategies; the industry in which we operate; expansion and opening of new locations; and opportunities and risks affecting our business, industry and financial results, including macroeconomic factors. These forward-looking statements involve risks and uncertainties, including: our ability to successfully design and execute our business strategy; our effectiveness at integrating and operating our past or future acquisitions; the effects of new or improved technologies or changes in consumer behavior; the potential for unfavorable publicity; our ability to obtain and renew leases on favorable terms or at all; our substantial indebtedness and covenants in our debt agreements restricting our ability to implement our business plan; our success in opening and operating new stores profitably and optimizing existing stores; risks related to our information systems and potential cybersecurity breaches or other privacy or data incidents; the cost and availability of certain commodities; our procurement of new games and entertainment offerings and our ability to obtain related licensing rights; the extensive laws and regulations in which we must comply with; and other risks identified in “Risk Factors” in our reports filed with the Securities and Exchange Commission. Accordingly, actual results may differ materially from the forward-looking statements, and the Company therefore cautions you against relying on such forward-looking statements. The Company intends these forward-looking statements to speak only as of the time of this release and does not undertake to update or revise them as more appropriate information becomes available, except as required by law.

___________________
¹ Available liquidity is defined as cash and cash equivalents plus availability under the Company’s $650.0 million revolving credit facility.

Non-GAAP Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”), the Company uses the following non-GAAP financial measures: Adjusted EBITDA, Credit Adjusted EBITDA (calculated in accordance with the Company’s Credit Facility), Net Total Leverage Ratio (calculated in accordance with the Company’s Credit Facility), Store operating income before depreciation and amortization, Adjusted net income (loss), Adjusted net income (loss) per share – diluted, and Adjusted free cash flow, reconciliations or numerical inputs of which can be found on the following pages (collectively the “non-GAAP financial measures”). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The Company uses these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. The Company believes that they provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. The non-GAAP measures used by the Company in this press release may be different from the measures used by other companies or calculated differently than similar measures used by other companies.

For Investor Relations Inquiries:

Investor@daveandbusters.com

DAVE & BUSTER’S ENTERTAINMENT, INC. Consolidated Statements of Operations (unaudited, in millions, except per share amounts)
		Three Months Ended													Six Months Ended
		August 4, 2026							August 5, 2025						August 4, 2026							August 5, 2025
Entertainment revenues		$	332.6			61.1	%		$	364.5		65.4	%		$	677.7			61.4	%		$	731.1		65.0	%
Food and beverage revenues			211.5			38.9	%			192.9		34.6	%			425.6			38.6	%			393.9		35.0	%
Total revenues			544.1			100.0	%			557.4		100.0	%			1,103.3			100.0	%			1,125.0		100.0	%
Cost of entertainment			30.7			9.2	%			29.2		8.0	%			58.1			8.6	%			59.8		8.2	%
Cost of food and beverage			52.5			24.8	%			47.2		24.5	%			104.9			24.6	%			98.8		25.1	%
Total cost of products			83.2			15.3	%			76.4		13.7	%			163.0			14.8	%			158.6		14.1	%
Operating payroll and benefits			140.2			25.8	%			138.7		24.9	%			280.3			25.4	%			273.7		24.3	%
Other store operating expenses			192.9			35.5	%			186.9		33.5	%			379.6			34.4	%			375.3		33.4	%
General and administrative expenses			27.1			5.0	%			32.0		5.7	%			54.6			4.9	%			56.3		5.0	%
Depreciation and amortization expenses			73.7			13.5	%			65.2		11.7	%			144.6			13.1	%			128.4		11.4	%
Pre-opening costs			6.7			1.2	%			4.1		0.7	%			12.1			1.1	%			10.1		0.9	%
Other charges and gains			0.9			0.2	%			1.1		0.2	%			2.8			0.3	%			6.4		0.6	%
Total operating costs			524.7			96.4	%			504.4		90.5	%			1,037.0			94.0	%			1,008.8		89.7	%
Operating income			19.4			3.6	%			53.0		9.5	%			66.3			6.0	%			116.2		10.3	%
Interest expense, net			38.0			7.0	%			38.7		6.9	%			74.9			6.8	%			75.5		6.7	%
Income (loss) before income taxes			(18.6	)		(3.4	)%			14.3		2.6	%			(8.6	)		(0.8	)%			40.7		3.6	%
Provision for (benefit from) income taxes			(6.1	)		(1.1	)%			2.9		0.5	%			(1.8	)		(0.2	)%			7.6		0.7	%
Net income (loss)		$	(12.5	)		(2.3	)%		$	11.4		2.0	%		$	(6.8	)		(0.6	)%		$	33.1		2.9	%
Net income (loss) per share:
Basic		$	(0.36	)					$	0.33					$	(0.20	)					$	0.96
Diluted		$	(0.36	)					$	0.32					$	(0.20	)					$	0.94
Weighted average shares used in per share calculations:
Basic shares			34.81							34.52						34.78							34.56
Diluted shares			34.81							35.14						34.78							35.08
Other information:
Company-owned stores at end of period			250							237						250							237
Store operating weeks in the period			3,204							3,066						6,364							6,081
Total revenue per store operating weeks in the period (in thousands)		$	170						$	182					$	173						$	185
Total revenue per square foot per store operating weeks in the period (in dollars)		$	4.15						$	4.43					$	4.23						$	4.49

(1)		All percentages are expressed as a percentage of total revenues for the respective period presented, except cost of entertainment, which is expressed as a percentage of entertainment revenues, and cost of food and beverage, which is expressed as a percentage of food and beverage revenues.

DAVE & BUSTER’S ENTERTAINMENT, INC. Other Financial Data (unaudited, in millions)
Condensed Consolidated Balance Sheets:
	August 4, 2026				February 3, 2026
ASSETS
Cash and cash equivalents	$	16.0			$	16.6
Other current assets		111.8				107.5
Total current assets		127.8				124.1
Property and equipment, net		1,739.9				1,719.0
Operating lease right of use assets		1,283.1				1,303.2
Intangible and other assets, net		970.1				970.3
Total assets	$	4,120.9			$	4,116.6
LIABILITIES AND STOCKHOLDERS’ EQUITY
Total current liabilities	$	430.7			$	434.6
Deferred income taxes		66.6				68.6
Operating lease liabilities		1,539.4				1,562.6
Other long-term liabilities		495.8				444.6
Long-term debt, net		1,500.5				1,515.0
Stockholders’ equity		87.9				91.2
Total liabilities and stockholders’ equity	$	4,120.9			$	4,116.6

Summary Cash Flow Information:
		Three Months Ended								Six Months Ended
		August 4, 2026				August 5, 2025				August 4, 2026				August 5, 2025
Net cash provided by (used in):
Operating activities:		$	46.8			$	34.0			$	160.6			$	129.8
Investing activities:			(84.7	)			(84.7	)			(190.0	)			(239.3	)
Financing activities:			34.3				50.8				28.8				114.6
Increase (decrease) in cash and cash equivalents		$	(3.6	)		$	0.1			$	(0.6	)		$	5.1

DAVE & BUSTER’S ENTERTAINMENT, INC. Non-GAAP Measures (unaudited, in millions)

Adjusted EBITDA:

Adjusted EBITDA represents net income (loss), plus interest expense, net, loss on debt refinancing, provision for (benefit from) income taxes, depreciation and amortization expense, (gain) loss on property and equipment transactions, impairment of long-lived assets, share-based compensation, currency transaction (gains) losses, transaction and integration costs, system implementation costs and certain other costs, as calculated below. Adjusted EBITDA is a non-GAAP financial measure commonly used in our industry and should not be construed as an alternative to net income as an indicator of operating performance or as an alternative to cash flow provided by operating activities as a measure of liquidity (as determined in accordance with GAAP). Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. Adjusted EBITDA is presented because we believe that it provides useful information to investors and analysts regarding our operating performance. By reporting Adjusted EBITDA, we provide a basis for comparison of our business operations between current, past and future periods by excluding items that we do not believe are indicative of our core operating performance. A reconciliation of net income (loss) to Adjusted EBITDA is provided below for the periods presented:

	Three Months Ended														Six Months Ended
	August 4, 2026(1)							August 5, 2025(1)							August 4, 2026(1)							August 5, 2025(1)
Net income (loss)	$	(12.5	)		(2.3	)%		$	11.4			2.0	%		$	(6.8	)		(0.6	)%		$	33.1			2.9	%
Add back:
Interest expense, net		38.0							38.7							74.9							75.5
Provision for (benefit from) income taxes		(6.1	)						2.9							(1.8	)						7.6
Depreciation and amortization expense		73.7							65.2							144.6							128.4
Share-based compensation(2)		0.9							7.9							3.4							10.9
Transaction and integration costs(3)		—							0.2							—							0.4
System implementation costs(4)		—							0.9							—							2.5
Loss on property and equipment transactions(5)		0.9							0.2							2.8							3.9
Other items, net(6)		4.0							2.4							4.9							3.5
Adjusted EBITDA, a non-GAAP measure(1)	$	98.9			18.2	%		$	129.8			23.3	%		$	222.0			20.1	%		$	265.8			23.6	%

(1)		All percentages are expressed as a percentage of total revenues for the respective period presented.
(2)		Non-cash share-based compensation expense, net of forfeitures, recorded in General and administrative expenses on the Consolidated Statements of Comprehensive Income (Loss).
(3)		Transaction and integration costs related to the acquisition and integration of Main Event recorded in General and administrative expenses on the Consolidated Statements of Comprehensive Income (Loss)
(4)		System implementation costs represent expenses incurred related to the development of new enterprise resource planning, human capital management and inventory software for our stores and store support teams. These charges are recorded in Other charges and gains on the Consolidated Statements of Comprehensive Income (Loss).
(5)		Loss on property and equipment transactions primarily represents the net book value of assets retired and certain costs associated with the retirement of those assets.
(6)		The amounts for the 2026 periods primarily consisted of severance and restructuring charges, one-time third-party legal consulting fees, a discrete legal settlement outside of the normal course of business, and various individually immaterial adjustments. The amount for the fiscal 2025 periods primarily consisted of discretionary retention incentives, one-time, third-party consulting fees, and severance costs.

Store Operating Income Before Depreciation and Amortization:

Store Operating Income Before Depreciation and Amortization, a non-GAAP measure, represents operating income, plus depreciation and amortization expense, general and administrative expenses, pre-opening costs and other gains and charges. We believe that Store Operating Income Before Depreciation and Amortization is another useful measure in evaluating our operating performance because it removes the impact of general and administrative expenses, which are not incurred at the store level, and the costs of opening new stores, which are non-recurring at the store level, and thereby enables the comparability of the operating performance of our stores for the periods presented. We also believe that Store Operating Income Before Depreciation and Amortization is a useful measure in evaluating our operating performance within the entertainment and dining industry because it permits the evaluation of store-level productivity, efficiency, and performance, and we use Store Operating Income Before Depreciation and Amortization as a means of evaluating store financial performance compared with our competitors. However, because this measure excludes significant items such as general and administrative expenses, pre-opening costs and other gains and charges, as well as our interest expense, net, loss on debt extinguishment/refinance and depreciation and amortization expense, which are important in evaluating our consolidated financial performance from period to period, the value of this measure is limited as a measure of our consolidated financial performance. A reconciliation of operating income to Store Operating Income Before Depreciation and Amortization is provided below for the periods presented:

	Three Months Ended														Six Months Ended
	August 4, 2026(1)							August 5, 2025(1)							August 4, 2026(1)							August 5, 2025(1)
Operating income	$	19.4			3.6	%		$	53.0			9.5	%		$	66.3			6.0	%		$	116.2			10.3	%
Add back:
General and administrative expenses		27.1							32.0							54.6							56.3
Depreciation and amortization expense		73.7							65.2							144.6							128.4
Pre-opening costs		6.7							4.1							12.1							10.1
Other gains and charges		0.9							1.1							2.8							6.4
Store operating income before depreciation and amortization, a non-GAAP measure	$	127.8			23.5	%		$	155.4			27.9	%		$	280.4			25.4	%		$	317.4			28.2	%

(1)		All percentages are expressed as a percentage of total revenues for the respective period presented.

Adjusted free cash flow:

Adjusted free cash flow, a non-GAAP measure, represents Net cash provided by operating activities less capital expenditures, plus payments received from landlords related to sale-leaseback transactions and finance leases. Management believes adjusted free cash flow provides investors with an additional measure of the cash generated by the business after considering routine capital investment requirements. A reconciliation of Net cash provided by operating activities to Adjusted free cash flow is provided below for the periods presented:

		Six Months Ended
		August 4, 2026				August 5, 2025
Net cash provided by operating activities		$	160.6			$	129.8
Less: Capital expenditures			(190.0	)			(243.8	)
Add: Incentives from landlords – finance leases			—				4.5
Add: Proceeds from sale-leaseback transactions			48.9				73.0
Adjusted free cash flow, a non-GAAP measure		$	19.5			$	(36.5	)

Credit Adjusted EBITDA and Net Total Leverage Ratio:

Credit Adjusted EBITDA, a non-GAAP measure, represents net loss plus certain items as defined at Adjusted EBITDA above, as well as certain other adjustments as defined in our Credit Agreement. These other adjustments include (i) entertainment revenue deferrals, (ii) the cost of new projects, including store pre-opening costs, (iii) business optimization expenses and other restructuring costs, and (iv) other costs and adjustments as permitted by the Credit Agreement. We believe the presentation of Credit Adjusted EBITDA is appropriate as it provides additional information to investors about the calculation of, and compliance with, certain financial covenants in the Credit Agreement. The following table sets forth a reconciliation of Net loss to Credit Adjusted EBITDA for the period shown:

		Trailing Four Quarters Ended August 4, 2026
Net loss		$	(88.7	)
Add back:
Interest expense, net			153.4
Loss on debt refinancing			—
Provision for income taxes			(28.6	)
Depreciation and amortization expense			295.6
Share-based compensation(1)			12.1
Transaction and integration costs(2)			0.3
System implementation costs(3)			0.9
Loss on property and equipment transactions and impairments(4)			35.7
Other items, net(5)			12.1
Pre-opening costs(6)			21.1
Credit Facility specific items, net(7)			21.9
Credit Adjusted EBITDA, a non-GAAP measure		$	435.8

(1)		See discussion of share-based compensation at Adjusted EBITDA above.
(2)		See discussion of transaction and integration costs at Adjusted EBITDA above.
(3)		See discussion of system implementation costs at Adjusted EBITDA above.
(4)		Consists of store asset impairments and loss on property and equipment disposals.
(5)		Primarily consists of discretionary retention incentives, severance costs and certain third-party consulting fees. The third-party consulting fees are not part of our ongoing operations and were incurred in association with a change in leadership to execute discrete, project-based strategic initiatives aimed at analyzing and summarizing growth opportunities and cost reductions for the Company. The transformative nature, narrow scope, and limited duration of these incremental consulting fees are not reflective of the ordinary course expenses incurred to operate our business. Third-party consulting fees, discretionary retention incentives and severance costs are included in General and administrative expenses on the Consolidated Statements of Comprehensive Income (Loss).
(6)		Represents costs incurred, primarily consisting of occupancy and payroll related expenses, associated with the opening of new stores. These costs are considered a “cost of new projects” as defined in our Credit Facility.
(7)		Represents other adjustments allowed under our Credit Agreement in the determination of Net Total Leverage Ratio including (i) amortization of software costs, (ii) executive search fees, (iii) public company costs, (iv) estimated impact of remodels to financial performance, (v) the pro forma impact of certain leases that were reclassified as finance leases during fiscal 2025 and (vi) the pro forma impact of certain implemented cost saving initiatives.

The following table provides a calculation of Net Total Leverage Ratio, as defined in the Credit Agreement, for the period shown:

	As of, and for the Trailing Four Quarters Ended August 4, 2026
Credit Adjusted EBITDA (a)	$	435.8
Total debt(1)		1,540.4
Less: Cash and cash equivalents		(16.0	)
Add: Outstanding letters of credit		18.9
Net debt (b)	$	1,543.3
Net Total Leverage Ratio (b / a)	3.5		x

(1)		Amount represents the sum of the carrying amount of debt outstanding and finance lease liabilities.

Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Share – Diluted:

Adjusted net income (loss), a non-GAAP measure, represents net income (loss) before special items, as calculated below, and Adjusted net income (loss) per share – diluted, a non-GAAP measure, represents Adjusted net income (loss) on a fully diluted, per share basis. We believe excluding these special items from net income (loss) provides investors with a clearer perspective of our ongoing operating performance and a more relevant comparison to prior period results. The following table presents a reconciliation of net income (loss) to Adjusted net income (loss) and presents Adjusted net income (loss) per diluted share, for the periods shown:

	Three Months Ended																Six Months Ended
	August 4, 2026								August 5, 2025								August 4, 2026								August 5, 2025
	$				Per Diluted Share				$				Per Diluted Share				$				Per Diluted Share				$				Per Diluted Share
Net income (loss) and net income (loss) per diluted share	$	(12.5	)		$	(0.36	)		$	11.4			$	0.32			$	(6.8	)		$	(0.20	)		$	33.1			$	0.94
Adjustments:
Transaction and integration costs(1)		—				—				0.2				0.01				—				—				0.4				0.01
System implementation costs(2)		—				—				0.9				0.03				—				—				2.5				0.07
Loss on property and equipment transactions(3)		—				—				0.2				0.01				0.0				0.00				3.9				0.11
Other items, net(4)		4.0				0.11				2.4				0.07				4.9				0.14				3.5				0.10
Tax impact of items above, net(5)		(1.0	)			(0.03	)			(0.9	)			(0.03	)			(1.3	)			(0.03	)			(2.7	)			(0.08	)
Adjusted net income (loss) and Adjusted net income (loss) per share – diluted, non-GAAP measures	$	(9.5	)		$	(0.27	)		$	14.2			$	0.40			$	(3.2	)		$	(0.09	)		$	40.7			$	1.16

(1)		See discussion of transaction and integration costs at Adjusted EBITDA above.
(2)		See discussion of system implementation costs at Adjusted EBITDA above.
(3)		Loss on property and equipment transactions primarily represents the net book value of assets retired and certain costs associated with the retirement of those assets.
(4)		See discussion of other items, net at Adjusted EBITDA above.
(5)		The income tax effect related to special items is based on the blended jurisdictional statutory tax rates for the applicable period.